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Abstract 
BACKGROUND. Ectopic pregnancy is a life-threatening condition for which novel screening tools that 
would enable early accurate diagnosis would improve clinical outcomes. Kisspeptins, encoded by KISS1, play 
an essential role in human reproduction, at least partially by regulating placental function and possibly 
embryo implantation. Kisspeptin levels are elevated massively in normal pregnancy and reportedly altered in 
various gestational pathologic diseases. Yet, the pathophysiologic role of KISS1/kisspeptin in ectopic 
pregnancy has not been investigated previously. 
OBJECTIVE. The purpose of this study was to evaluate changes of KISS1/kisspeptin levels in ectopic 
pregnancy and their underlaying molecular mechanisms and to ascertain the diagnostic implications of these 
changes. 
STUDY DESIGN. A total of 122 women with normal pregnancy who underwent voluntary termination of 
pregnancy and 84 patients who experienced tubal ectopic pregnancy were recruited. Measurements of plasma 
kisspeptins and KISS1 expression analyses in human embryonic/placental tissue were conducted in ectopic 
pregnancy and voluntary termination of pregnancy control subjects during the early gestational window (<12 
weeks). Putative microRNA regulators of KISS1 were predicted in silico, followed by expression analyses of 
selected microRNAs and validation of repressive interactions in vitro. Circulating levels of these microRNAs 
were also assayed in ectopic pregnancy vs voluntary termination of pregnancy. 
RESULTS. Circulating kisspeptins gradually increased during the first trimester of normal pregnancy but 
were reduced markedly in ectopic pregnancy. This profile correlated with the expression levels of KISS1 in 
human embryonic/placental tissue, which increased in voluntary termination of pregnancy but remained 
suppressed in ectopic pregnancy. Bioinformatic predictions and expression analyses identified miR-27b-3p 
and miR-324-3p as putative repressors of KISS1 in human embryonic/placental tissue at <12 weeks gestation, 
when expression of microRNAs was low in voluntary termination of pregnancy control subjects but 
significantly increased in ectopic pregnancy. Yet, a significant repressive interaction was documented only 
for miR-324-3p, occurring at the predicted 3’-UTR of KISS1. Interestingly, circulating levels of miR-324-3p, 
but not of miR-27b-3p, were suppressed distinctly in ectopic pregnancy, despite elevated tissue expression of 
the pre-microRNA. A decision-tree model that used kisspeptin and miR-324-3p levels was successful in 
discriminating ectopic pregnancy vs voluntary termination of pregnancy, with a receiver-operating 
characteristic area under the curve of 0.95±0.02 (95% confidence interval). 
CONCLUSION. Our results document a significant down-regulation of KISS1/kisspeptins in early stages of 
ectopic pregnancy via, at least partially, a repressive interaction with miR-324-3p. Our data identify 
circulating kisspeptins and miR-324-3p as putative biomarkers for accurate screening of ectopic pregnancy at 
early gestational ages. 
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Ectopic pregnancy (EP) is defined as the implantation and development of a fertilized ovum 
elsewhere than in the uterine cavity. The fallopian tube is the most common site for ectopic 
implantation,
1
 which otherwise might occur also in the cervix, ovary, abdomen, or even a scar of a 
previous cesarean delivery. Approximately, 1.5–2% of all reported pregnancies are extrauterine.
2
 
Despite substantial improvements in its timely management, EP remains the early pregnancy 
complication with the highest morbidity and mortality rates.
2
 EP can result in tubal rupture if not 
managed promptly, thereby compromising woman’s health and future fertility.
3
 Although the 
overall incidence of EP increased by 6-fold between the 1970s and 1990s, its associated mortality 
rate has substantially fallen, largely because of better diagnosis and treatment before rupture.
2
 
Nonetheless, EP still represents 9–13% of all pregnancy-related deaths in developed countries and 
is responsible for approximately 75% of deaths of the first trimester. The situation is much worse 
in developing countries; for instance, in Africa, women with EP encounter high fatality rates 
because of late diagnosis, where it accounts for up to 30% of pregnancy-associated deaths.
4
 Thus, 
there is an important clinical need to improve our understanding of the pathophysiologic basis of 
EP and to develop better tools for accurate early screening and diagnosis of this condition. 
 
It is assumed that EP is multifactorial in origin, with several contributing factors, that include 
morphologic or functional alterations of fallopian tube permeability, perturbed chemotactic tubal 
environment, and/or deregulated tubal motility; the major risks factors for EP are a history of tubal 
surgery and/or extrauterine pregnancy.
3
 However, in more than one-half of cases of EP, no risk 
factor can be identified, which suggests the existence of additional, as yet unknown, underlying 
mechanisms. Current diagnosis of EP is based mainly on transvaginal ultrasonography, together 
with serial measurements of the β-subunit of human chorionic gonadotropin (β-hCG)
5
, although 
laparoscopy is often needed as a method of certainty. Indeed, although ultrasound scans and β-
hCG tests are extremely powerful for early detection of pregnancy and identification of some of its 
eventual complications, their sensitivity and specificity substantially decrease in the case of 
pregnancies of unknown location,
3
 in which false-positive or -negative diagnosis may occur. In 
this context, it is especially crucial to avoid erroneous diagnosis of a pregnancy as nonviable, 
because it may lead to medical or surgical interventions that could eliminate or severely damage a 
healthy pregnancy.
5
 Accordingly, different biomarkers have been proposed to increase the 
accuracy of EP diagnosis, which would allow a rapid triage of pregnancies at risk of extrauterine 
location. These putative markers may include circulating levels of progesterone, estradiol, 
vascular-endothelial growth factor-A, inhibin-A, and activin-A.6, 7, 8, 9, 10, 11 Yet, despite 
promising results,
11
 there is little pathogenic information emerging from these studies, and no 
diagnostic test based on these markers is currently available in clinical practice for accurate 
biochemical identification of EP. 
 
Kisspeptins, the products of the KISS1 gene, have emerged in the last decade as master 
regulators of reproductive function in multiple species, including humans,
12
 as illustrated by the 
fact that patients with inactivating mutations of KISS1 or the cognate kisspeptin receptor, GPR54 
(aka, KISS1R), experience severe hypogonadism of central origin.13, 14, 15 Despite the 
overwhelming evidence that supports a major function of brain (hypothalamic) kisspeptin 
signaling in the control of reproduction, mainly via its capacity to stimulate gonadotropin-
releasing hormone neurons,
16
 additional functions of kisspeptins have been reported at peripheral 
levels of the reproductive axis, which includes the ovary and the uterus.17, 18 On the latter, 
mounting evidence has demonstrated that the elements of Kiss1 system are expressed in human 
endometrium and placenta,
18
 and kisspeptins have been proposed to play an important role in 
endometrial gland development and function
19
 and in human placentation.17, 18 Notably, 
expression and functional analyses have suggested that kisspeptin signaling is an important 
(negative) regulator of human trophoblast migration and invasion
20
 and a (positive) regulator of 
embryo implantation.
18
 Altogether, these findings attest a relevant function of kisspeptins in 
human placentation, which is further suggested by the fact that circulating levels of kisspeptins 
dramatically increase during gestation,
21
 with abundant expression of KISS1 in human trophoblast, 
especially in the first trimester.
20
 Accordingly, inappropriately low kisspeptin levels have been 
proposed as a biomarker of gestational alterations, such as intrauterine growth restriction and 
preeclampsia,22, 23 and a putative predictor of miscarriage risk.
24
 In fact, a very recent study that 
compared a well-defined, as yet limited (N=20), population of women with viable intrauterine 
pregnancy vs women with confirmed spontaneous abortion suggested that kisspeptin levels during 
an early gestational window (weeks 6–10) might serve as a good biomarker of pregnancy 
viability.
25
 However, to our knowledge, no single study has addressed potential dynamic changes 
in KISS1/kisspeptin in EP and their eventual diagnostic utility in this condition. 
 
The molecular mechanisms underlying EP remain largely unknown. Interestingly, recent 
studies have highlighted the potential contribution of deregulated microRNAs as putative 
pathogenic and/or diagnostic factors in EP. MicroRNAs are small, noncoding RNAs that can 
modulate (mainly repress) gene/protein expression, primarily via interaction with seed regions at 
the 3’ untranslated region (3’-UTR) of target genes, thereby promoting messenger RNA (mRNA) 
degradation or preventing protein translation.
26
 Deregulation of microRNA expression in 
embryonic/placental tissues and the fallopian tube has been reported in EP.27, 28, 29 These 
studies have revealed changes in the expression patterns of microRNAs of the let7 family and 
miR-132, miR-145, miR149, miR-182, miR-196, miR-223, and miR-424 in ectopic implantation; 
yet, the putative mechanistic implications for these alterations are yet to be elucidated. In addition, 
changes in the circulating levels of some microRNAs have been associated to EP.30, 31 Thus, 
miR-323-3p reportedly was increased in women with EP,
32
 whereas additional studies have shown 
that circulating levels of miR-515-3p, miR-517a, miR-518b, miR-519d, miR-525-3p, and miR-873 
are significantly lower in patients with ectopic implantation.32, 33, 34 Likewise, abnormal serum 





Considering that microRNAs in blood are, in general, stable and relatively easy to detect,
30
 
these data hold promise for the identification of a novel class of noninvasive biomarkers of EP. 
Yet, to date, no single diagnostic test based on the determination of microRNAs (alone or in 
combination) has been validated as reliable biomarker of EP. Moreover, despite recent evidence on 
the epigenetic control of hypothalamic Kiss1 in rodents,
36
 to our knowledge, no single report has 
documented the existence of microRNA-mediated regulation of human KISS1. 
 
In the aforementioned context, the aims of our work were (1) to evaluate potential changes in 
KISS1 mRNA expression (at embryonic/placental tissue) and circulating kisspeptin levels in EP 
and (2) to highlight eventual regulatory mechanisms of KISS1 expression in ectopic gestation, 
which involves microRNAs. We particularly have targeted an early gestational window (<12 




The present study was approved by the Institutional Review Board/Independent Ethics 
Committee of the Hospital Universitario La Fe, Valencia, Spain. Early embryonic/placental tissue 
(mostly trophoblast) was collected after obtaining the corresponding informed consent from each 
patient, as described elsewhere.28, 29 
Sample collection 
A total of 122 women with a normal ongoing pregnancy who desired a voluntary termination 
of pregnancy (VTOP) and 84 patients who experienced from tubal EP were recruited over a >4-
year period, according to previous described criteria,28, 29 from whom plasma and/or 
embryonic/placental tissues were obtained. All individuals (EP and VTOP) included in this study 
signed an informed consent, and samples were dated properly according to the last menstrual 
period (week of pregnancy). Because of operational reasons, related with the sequential 
recruitment of cases over a protracted period of time by different personnel, it was not possible to 
obtain plasma and tissue samples, of sufficient quality for hormonal or molecular analyses, from 
all recruited patients. Likewise, because of limitations in the amount of the biologic materials that 
were sampled from some patients, not all analytes could be assayed in each sample, especially 
when different procedures (eg, radioimmunoassay vs quantitative polymerase chain reaction 
[qPCR]) were involved. Accordingly, the final group sizes per type of sample and analyte were (1) 
plasma kisspeptin (VTOP, 88; EP, 45), (2) plasma microRNAs (VTOP, 58; EP, 31), (3) tissue 
KISS1 (VTOP, 49; EP, 21), and (4) tissue microRNAs (VTOP, 90; EP, 35). Details about 
distribution of samples according to gestational age are provided in the Table. 
 
The diagnosis of EP was based on clinical and physical examination, transvaginal ultrasound 
scans, and serial quantitative hCG levels and confirmed by laparoscopy, as described by Barnhart,
1
 
in which the tissue was removed, in line with previously published procedures of our team.28, 29 
The EP patients did not receive methotrexate treatment, and laparoscopy was performed in the 
following manner: ectopic pregnancies that were selected for this study were unruptured gestations 
located in the isthmus or the proximal ampulla. The tube that contained the EP was grasped at both 
sides (approximately 1 cm away from the gestation site), and bipolar coagulation was applied. 
Similarly, the adjacent mesentery was also coagulated. Then, salpingectomy was performed with 
the use of scissors, as standard procedure to avoid recurrence of EP; a longitudinal antimesenteric 
incision into the surface of the tube was made, and mild pressure was applied with 2 fingers to 
extract the gestational sac. Embryonic tissue was carefully separated from obvious blood clots or 
tubal tissue in the operating room under a stereomicroscope and was immediately placed in TRIzol 
reagent, frozen, and stored at –80°C until use. A piece of each sample was sent to the Pathology 
Department (Hospital Universitario La Fe, Valencia) to provide histologic confirmation of EP and 
the absence of tubal tissue. The fetal dilation and evacuation method or fetal aspiration technique 
was performed in VTOP women to obtain the embryonic tissue. 
  
RNA extraction and qPCR 
Total RNA was isolated from embryonic tissues and maternal plasma samples from different 
stages of pregnancy (both control and ectopic gestations), with the use of TRIzol reagent 
(Invitrogen, Carlsbad, CA), according to the manufacturer’s protocol. The quality and 
concentration of the isolated RNA were determined by spectrophotometry, according to standard 
procedures. Real-time qPCR was performed on the samples with a Bio-Rad SFX 96 Real-Time 
System (Bio-Rad Laboratories, Hercules, CA), as described in detail elsewhere.
37
 For 
quantification of KISS1 mRNA in embryonic samples, 1 μg of total RNA per tissue sample was 
treated with RQ1 RNAse-free DNAse-I (Promega, Madison, WY) and retro-transcribed in a 30 μL 
reaction with the use of iScript Reverse Transcription Super-mix (Bio-Rad Laboratories). For real-
time PCR amplification, we used SYBR Green qPCR Master Mix (Promega), with the following 
primer sequences: hKISS1-forward: 5′-AGC AGC TAG AAT CCC TGG G-3′, position 10698–
10716 nt; hKISS1-reverse: 5′-AGG CCG AAG GAG TTC CAG T-3′, position 10947–10929 nt. 
The primer pair: hL19-forward: 5′-GAA ATC GCC AAT GCC AAC TC-3′ and hL19-reverse: 5′-
ACC TTC AGG TAC AGG CTG TG-3′ was used for amplification of a 290-base pair fragment of 
the mRNA of ribosomal L19 protein, which served as internal control for reaction efficiency and 
sample loading. PCR was initiated by 1 cycle of 95°C for 2 minutes, followed by 35 cycles of 15 
seconds at 95°C, 30 seconds at 62°C, and 10 seconds at 72°C, followed by 1 final cycle of 72°C 
for 1 minute. Relative KISS1 mRNA levels were normalized against the expression levels of L19 
transcript. 
 
For microRNA analyses in embryonic tissue and plasma samples, quantification of the 
expression levels of miR-324-3p and miR-27b-3p was performed according to “miRCURY LNA 
Universal RT microRNA PCR individual assay - Instruction manual v6.2”, as instructed by Exiqon 
(Vedbaek, Denmark). All microRNAs were reverse transcribed into complementary DNA in a 
single reaction step. The complementary DNA synthesis control (UniSp6) was added in the 
reverse transcription reaction, which gave us the opportunity to evaluate the retro-transcribed 
reaction. Complementary DNA and SYBR Green qPCR Master Mix (Promega) were transferred 
to the qPCR plate with specifics primers (Exiqon). 
 
The final qPCR expression data for both mRNA (KISS1) and microRNA were obtained by the 
2▵▵
Ct
 method, according to the original qPCR equation =2
–[▵Ct reference▵Ct target]; the cycle threshold 
values from the ≤6 week normal pregnancy group were used as reference, to provide relative units 
of expression. The same method was used to calculate the values of housekeeping internal control, 
L19 (mRNA) or U6 (microRNAs) in case of tissue samples and hsa-miR-191-5p for plasma. 
Finally, the ratio between sample and housekeeping was calculated to express relative 
units/internal control. For presentation, the final data were multiplied by 100. 
 
Note that, because of the differences in the length and nucleotide composition of the transcripts 
to be amplified and in the chemistry used for effective PCR amplification, technically reliable 
detection of microRNAs was achieved in a higher number of placental samples than KISS1 
(Table 1). 
  
Table. Group sizes and gestational age distribution for the different tissues and analytes assayed in the cohorts of women 
with normal and ectopic pregnancies 
Gestational 
week 




















            
≤6 10 27  9 16  6 13  9 16 
7 18 8  9 4  4 3  11 9 
8 12 5  10 5  8 2  13 3 
9–12 25 6  13 6  17 3  25 7 
Total ≤6–12 65 45  41 31  35 21  58 35 
13–15 14 —  9 —  10 —  20 — 
16–17 6 —  5 —  2 —  7 — 
18–20 3 —  3 —  2 —  5 — 
TOTAL 88 45  58 31  49 21  90 35 
            
 
Note: For operational reasons related with the sequential recruitment of cases over a protracted period of time by different 
personnel, it was not possible to obtain plasma and tissue samples of sufficient quality for hormonal or molecular analyses 
from all recruited patients. Likewise, because of limitations in the amount of the biologic materials that were sampled from 
some patients, not all analytes could be assayed in each sample, especially when involving different analytical procedures. 
The numbers in the Table correspond to effective individual analyses that were conducted per group and yielded 
technically reliable results. 
Romero-Ruiz et al. Kisspeptin and miR-324-3p in ectopic pregnancy. Am J Obstet Gynecol 2019. 
Bioinformatic analysis 
Computational microRNA target prediction algorithms were applied to propose putative 
interactions between the UTR of KISS1 and validated human microRNAs in available databases. 
Algorithms for the prediction of microRNAs, which can putatively regulate KISS1, were applied to 
the 3’-UTR and 5’ promoter regions, with the following inclusion criteria: (1) microRNAs 
predicted for interaction at the 3’-UTR had to be identified at least in 2 of the following databases: 
TargetScan (http://www. targetscan.org/; miRWalk (http://zmf.umm.uni-
heidelberg.de/apps/zmf/mirwalk2/); MicroCosm (http://www.ebi.ac. uk/enright-
srv/microcosm/htdocs/targets/v5/); or miRanda (http://www. microrna.org/microrna/ home/); (2) 
microRNAs predicted for interaction at the promoter region had to be identified with the use of the 
database miRWalk (http://mirwalk.umm.uni-heidelberg.de); and (3) for selected targets, 
conservation of at least 7 nucleotides at the seed region, complementary with KISS1 sequence, was 
required. 
Luciferase reporter assays 
HEK-293T cells (human embryonic kidney cells) were maintained in Dulbecco modified Eagle 
medium that was supplemented with 10% fetal bovine serum, 2 mmol/L L-glutamine, and 1% 
(volume/volume) penicillin/streptomycin at 37°C in a humidified atmosphere that contained 5% 
CO2. Transient transfections were performed with Rotifect (Carl Roth, Karlsruhe, Germany) 
according to manufacturer’s instructions. The expression vectors for Gluc-KISS1-3’UTR reporter, 
hsa-miR-324-3p, hsa-miR-27b-3p, and related reagents were purchased from GeneCopoeia 
(Rockville, MD); luciferase assay was performed with Secret-Pair Dual Luminescence Assay Kit 
according to the manufacturer’s instructions (Promega). For KISS1-3’UTR reporter assays, HEK-
293T cells were co-transfected with KISS1-3’UTR reporter and hsa-miR-324-3p expression 
vectors. For KISS1 promoter analyses, cells were co-transfected with a KISS1-promoter-Gluc 
reporter plasmid (KISS1p1339; a gift from Dr Sabine Heger, University of Hanover, Germany) 
and the hsa-miR-27b-3p expression vector. A schematic of the 3’-UTR and 5’-UTR KISS1 
reporter plasmids is presented in Supplemental Figure S1. As control subjects, cells co-transfected 
with the reporter vectors (KISS1-3’UTR or KISS1p1339) together with microRNA empty vectors 
or vectors harboring corresponding scramble hsa-miR sequences were included in all assays. Cells 
were collected in phosphate-buffered saline solution after 24 hours and lysed according to the 
instructions of the luciferase assay kit. Luciferase activity was measured with an Autolumat LB 
9510 (EG&G Berthold, Bad Wildbad, Germany). 
Assays for kisspeptins and total hCG 
Plasma kisspeptin levels were assayed in control (VTOP) and EP samples with a validated 
radioimmunoassay;38, 39 collection of blood samples was done in strict adherence to conditions 
known to preserve kisspeptins for proper immunometric detection.
40
 The kisspeptin antibody, 
GQ2, which was used at a final dilution of 1:3.500.000, has 100% cross-reactivity with human 
kisspeptin-54 and shorter fragments (kisspeptin-14 and -10), but <0.01% with any other related 
human RFamide peptides.
39
 Kisspeptin-54 was labeled with 
125
I by the Iodogen (Lund, Sweden) 
method. The assay was performed in duplicate with the use of dilutions of neat plasma in 0.7 mL 
of 0.06 M phosphate buffer, with 0.3% bovine serum albumin, incubated for 3 days at 4°C. Free 
and antibody-bound labels were then separated by charcoal adsorption. The assay detected changes 
of 2 pmol/L of plasma kisspeptin immunoreactivity with a 95% confidence limit. The intra- and 
interassay coefficients of variation were 8.3 and 10.2%, respectively. 
 
For comparative purposes, the levels of total hCG were also assayed in a subgroup of the 
VTOP and all available EP samples from the cohort in which plasma measurements of kisspeptins 
were conducted. The hCG assay was carried out according to the instructions of Human hCG 
ELISA Kit from Thermo-Fisher Scientific (Catalogue No# EHCG). In this research (nonclinical) 
assay, the capture antibody detects the α-subunit and cross-reacts with the whole molecule of hCG, 
and the detection antibody detects the β-subunit and cross-reacts with the whole molecule of hCG; 
this assay expresses results as picograms per milliliter units, which can be converted into milli-
international units per milliliter, considering an activity of the standard of the curve of 17.100 IU 
per mg, as reported by the manufacturer. This assay was applied to a subset of women with the 
VTOP group, during the first trimester of pregnancy, as control subjects (n=35 women) and to the 
whole cohort of patients who experienced tubal EP (n=45 women). 
Statistical analyses 
Data of microRNA and KISS1/kisspeptin levels are expressed as medians with their 
interquartile range. A nonparametric Mann-Whitney test was used to evaluate differences between 
case and control groups (single comparisons). Analysis of variance was used for statistical 
analyses of multiple datapoints; when appropriate, the post-hoc Fisher least significant difference 
test was applied to identify individual differences after multiple comparisons. For data that 
followed normal distribution, results are expressed as means±standard deviation or standard error 
of the mean; statistical differences were assessed with the use of 2-tailed Student t tests (single 
comparisons) or analysis of variance for statistical analyses of multiple datapoints, followed when 
appropriate by post-hoc, Newman-Keuls tests. All statistics were carried out with the use of Prism 
7.0c (GraphPad Software, Inc, San Diego, CA). A probability value of <.05 was considered to be 
statistically significant. 
  
Data of patients that were collected during the first 12 weeks of gestation were used to test the 
ability of kisspeptins, miR324-3p, and total hCG to predict EP. Different combinations of these 
variables were used after logarithmic transformation to build logistic regression models. Because 
of the limited number of cases, data were not divided into training and testing sets. On the 
contrary, models were built and validated with the use of repeated 10-fold cross-validation.
41
 K-
fold cross-validation randomly divides the data into k blocks of roughly equal size. Each block is 
left out in turn; the other k-1 blocks are used to train the model that is then used to predict the class 
of the remaining “left-out” subsample. Finally, classification results are summarized into 
performance measures and averaged to get the overall resampled estimate. 
 
Area under the curve (AUC), sensitivity, specificity, accuracy (total correct predictions/total 
samples), and Cohen’s (unweighed) Kappa statistic were computed for each variable’s 
combination within the cross validation process (kisspeptin, miR324-3p, hCG, hCG/miR-324-3p, 
hCG/kisspeptin, and kisspeptin/miR-324-3p). Model performance was measured with the use of 
AUC, sensitivity, and specificity. Cutoff values were calculated with receiver-operating 





According to the same validation procedure, a decision tree with the use of miR-324-3p and 
kisspeptin, with or without hCG, was built. The C50 method (an extension of the C4.5 
classification algorithm described in https://github.com/topepo/caret/) was used for this purpose. 
All models were built and validated using the R package caret, as defined in 
http://www.rulequest.com/see5-unix.html. 
Results 
Embryonic/placental tissue expression of KISS1 and circulating levels of kisspeptins in EP 
Dynamic profiles of embryonic/placental KISS1 expression and circulating levels of 
kisspeptins were compared between women with normal gestation who underwent VTOP (taken 
as control pregnancies) and women who experienced EP. For clinical reasons, we focused our 
analyses in a gestational window up to 12 weeks. For reference purposes, in the control group, 
additional samples from viable pregnancies up to 20 weeks of gestation were also included. 
Because of the limited number of samples available at early gestational ages and to increase 
statistical power, samples from 4, 5, and 6 weeks of gestation were grouped for analysis, as ≤6-
week sample. Likewise, in some analyses, data from VTOP samples at the intervals 7–9, 10–12, 
13–15, and 16–17 weeks of gestation were pooled together. For the same reasons, samples from 
control pregnancies at or beyond week 18 of gestation were grouped as 18- to 20-week samples. 
 
Analysis of KISS1 gene expression in embryonic/placental tissue from women who underwent 
VTOP revealed negligible expression in ≤6-week samples, with a significant increase thereafter, 
which reached a maximum >10,000-fold rise at week 12 of gestation. This was followed by a 
consistent, gradual decline in relative KISS1 levels from gestational week 13 onwards, with 
relative expression levels that had returned to ≤6-week values in the ≥18-week sample (Figure 1, 
A). Circulating levels of kisspeptins followed a grossly similar profile during early gestation, with 
an ascending curve in the initial weeks of normal pregnancy and concentrations that increased 





Figure 1. Expression of KISS1 in embryonic/placental tissue and plasma kisspeptin levels in normal and ectopic 
pregnancies 
A and B, Expression of KISS1 and kisspeptin levels in normal pregnancy (from voluntary termination of pregnancy) are 
grouped in 6 gestational age ranges: ≤6, 7–9, 10–12, 13–15, 16–17, and 18–20 weeks of pregnancy. Analyses in ectopic 
pregnancies were restricted to samples collected until week 12 of ectopic gestation. C and D, Integral levels of KISS1 
expression and plasma kisspeptin levels in samples from normal pregnancy and ectopic pregnancy up to week 12 of 
gestation are shown. E and F, The detailed temporal course of these changes. Samples from weeks 5 and 6 of gestation 
were grouped as ≤6 weeks, whereas those from weeks 9–12 were grouped as ≥9-week samples. Data are presented as 
medians and interquartile ranges. For presentation of KISS1 microRNA levels, data from the ≤6-week normal pregnancy 
group were used as reference values to provide relative units of expression, which were normalized against the internal 
control, L19. One asterisk indicates P<.05; 2 asterisks indicate P<.01; and 3 asterisks indicate P<.001 vs corresponding 
values in normal pregnancy (Mann-Whitney test for single comparisons in panels C and D or analysis of variance followed 
by Fisher least significant difference test). 
EP, ectopic pregnancy; mRNA, messenger RNA; NP, normal pregnancy; RU, relative units. 
Romero-Ruiz et al. Kisspeptin and miR-324-3p in ectopic pregnancy. Am J Obstet Gynecol 2019. 
 
  
Similar analyses of KISS1 expression and circulating kisspeptins were conducted in samples 
from women with EP, collected up to gestational week 12. When calculated as median and 
interquartile range values during the whole study period (<12 week), both embryonic/placental 
KISS1 gene expression and circulating kisspeptin levels were significantly suppressed in women 
with EP vs VTOP (Figure 1, C-D). To precisely monitor the timing of such suppression, data 
analysis was split in ≤6, 7, 8, and ≥9 weeks of gestation. In terms of KISS1 mRNA in 
embryonic/placental tissue, expression levels were equally negligible in the ≤6-week groups from 
VTOP and EP; yet, from week 7 onward, control pregnancies showed higher KISS1 mRNA levels 
than EPs, although differences were in the limit of statistical significance up to week 9 of 
pregnancy (Figure 1, E). Circulating levels of kisspeptins followed globally similar profiles, 
although in this case, plasma concentrations of kisspeptins were significantly lower in EP groups 
all through the study period, from week 7 until ≥9 weeks of pregnancy (Figure 1, F). 
Embryonic/placental tissue expression of miR-324-3p and miR-27b-3p in EP 
In an attempt to discover putative regulators that are responsible for the suppression of KISS1 
expression in EP, bioinformatics was applied to identify potential microRNA regulators by 
identification of their corresponding seed regions in the 3’-UTR (or eventually promoter) of the 
KISS1 gene. By a search of different databases and implementation of appropriate tools, 3 major 
putative candidates were identified: miR-137-3p and miR-324-3p (for which 8 and 7 nucleotides, 
respectively, from their predicted seed regions were found in the 3’-UTR of KISS1) and miR-27b-
3p, with 7 nucleotides of its seed region complementary to KISS1 promoter sequence 
(Supplemental Figure S1). Expression analyses subsequently were applied to evaluate the levels of 
these microRNAs at early stages of gestation. Our analyses documented that, although miR-324-
3p and miR-27b-3p are detectable readily in human embryonic/placental tissue during the first 
trimester of gestation, miR-137 is not, which therefore suggests negligible expression of this 
microRNA, which was excluded from further analyses. 
 
Detailed expression analyses in embryonic/placental tissue from control pregnancies during the 
first 20 weeks of gestation demonstrated roughly similar expression profiles for both miR-324-3p 
and miR-27b-3p, with rather low relative expression levels during early stages of gestation, and a 
significant increase after week 13 (miR-324-3p) or week 16 (miR-27b-3p) of pregnancy (Figure 2, 
A-B). Similar analyses revealed that the expression levels of both microRNAs were elevated 
significantly in embryonic/placental tissue from EP that, when calculated as median values during 
the whole study period (<12 weeks of gestation), represented a 4-fold (miR-324-3p) and 3-fold 
(miR-27b-3p) increase vs VTOP levels (Figure 2, C-D). Timed analysis of such differences 
revealed that elevated expression of both microRNAs mainly concentrated at early stages, up to 





Figure 2. Expression of miR-324-3p and miR-27b-3p in embryonic/placental tissue in normal and ectopic pregnancies 
A and B, Expression levels of miR-324-3p and miR-27b-3p in embryonic/placental tissue from control pregnancies (normal 
pregnancy; from voluntary termination of pregnancy) are presented, grouped in 6 gestational age ranges: ≤6, 7–9, 10–12, 
13–15, 16–17, and 18–20 weeks of pregnancy. Analyses in ectopic pregnancy were restricted to samples collected until 
week 12 of ectopic gestation. C and D, Integral levels of miR-324-3p and miR-27b-3p in samples from normal pregnancy 
and ectopic pregnancy up to week 12 of gestation are shown. E and F, The detailed temporal course of these changes is 
shown. Samples from week 5–6 of gestation were grouped as ≤6 week, whereas those from week 9–12 were grouped as ≥9 
week samples. Data are presented as medians and interquartile ranges. For presentation, data from the ≤6-week normal 
pregnancy group were used as reference values to provide relative units of expression, which were normalized against the 
internal control, U6. One asterisk indicates P<.05; 2 asterisks indicate P<.01; and 3 asterisks indicate P<.001 vs 
corresponding values in normal pregnancy (Mann-Whitney test for single comparisons in panels C and D or analysis of 
variance followed by Fisher least significant difference test). 
EP, ectopic pregnancy; mRNA, messenger RNA; NP, normal pregnancy; RU, relative units. 
Romero-Ruiz et al. Kisspeptin and miR-324-3p in ectopic pregnancy. Am J Obstet Gynecol 2019. 
 
  
Regulation of KISS1 expression by miR-324-3p and miR-27b-3p 
Based on bioinformatic predictions on the location of seed regions of miR324-3p and miR27b-
3p at the 3’- and promoter region of the KISS1 gene, respectively, and the reciprocal changes in 
expression levels of these microRNAs and their putative target (KISS1/kisspeptins) in EP, we 
sought to demonstrate whether a direct repressive interaction actually exists, using proper 
luciferase reporter assays in vitro. For testing miR-324-3p/KISS1 interactions, HEK-293T cells 
were co-transfected with Gluc-KISS1-3’UTR and miR-324-3p reporter plasmids; the former 
harboring the KISS1 3’-UTR that contains the putative miR324-3p seed region downstream the 
coding sequence of luciferase. As shown in Figure 3, A, over-expression of miR324-3p induced a 
significant 30% drop in luciferase activity, therefore demonstrating a direct interaction and 
negative posttranscriptional regulation of KISS1 gene by miR-324-3p at its 3’-UTR. In contrast, 
given the predicted location of the seed region of miR-27b-3p at the promoter of KISS1, a reporter 
construct harboring the human KISS1 promoter region upstream, the luciferase coding sequence 
was used. HEK-293T cells were co-transfected with KISS1-promoter-GLuc and miR-27b-3p 
expression vectors. However, as shown in Figure 3, B, no significant changes in luciferase activity 
were found after miR-27b-3p over-expression in this heterologous cell system. An integrative 
model that depicts the putative repressive mechanism where-by miR-324-3p, but not miR-27b-3p, 





Figure 3. Potential interaction of miR-324-3p and miR-27b-3p with KISS1 in vitro 
HEK-293T cells were co-transfected with 1 of the following reporter plasmid: A, KISS1-3’UTR-Gluc or B, KISS1-
promoter-GLuc together with a plasmid encoding the indicated microRNA (miR-324-3p) or miR-27b-3p or a microRNA 
scrambled control. Luciferase activity was measured as relative light units and is presented for each microRNA as 
percentage of inhibition with respect to control values (ie, cells transfected with the corresponding reporter plasmid 
together with the microRNA empty vector). As additional control, data from HEK-293T cells co-transfected with scramble 
has-miR vectors are also shown. Data are presented as the mean±standard deviation of n=3 experiments, which were done 
in triplicate. The asterisk indicates P<.05 (analysis of variance followed by Newman-Keuls test). C, A schematic is shown 
that depicts the proposed repressive mechanism, whereby miR-324-3p, acting at specific seed regions of the 3’-UTR of 
KISS1, suppresses expression, most likely by preventing its translation into kisspeptin protein. This would result in 
lowering of kisspeptin export to plasma (arrows) as seen in ectopic pregnancy conditions. Enhanced miR-324-3p in ectopic 
pregnancy is the consequence of increased expression of its pre-microRNA. 
Ctrl, control; Kp, kisspeptin; miRNA, microRNA. 
Romero-Ruiz et al. Kisspeptin and miR-324-3p in ectopic pregnancy. Am J Obstet Gynecol 2019. 
  
Circulating levels of miR-324-3p and miR-27b-3p in EP 
Collectively, our results suggested that miR-324-3p and miR-27b-3p are deregulated in EP and 
that these changes (especially for miR-324-3p) may be relevant mechanistically for the observed 
suppression of KISS1/kisspeptin in ectopic gestations. To ascertain whether tissue alterations 
translate into detectable changes in the circulating levels of these microRNA, qPCR analyses were 
applied to plasma samples from VTOP and EP during the early gestational window. Circulating 
levels of miR-324-3p and miR-27b-3p were detectable in control (VTOP) pregnant women all 
through the study period, up to week 20 of gestation, with rather stable values (Figure 4, A-B); 






Figure 4. Plasma levels of miR-324-3p and miR-27b-3p in normal and ectopic pregnancies 
A and B, Plasma levels of miR-324-3p and miR-27b-3p in samples from control pregnancies (normal pregnancy; from 
voluntary termination of pregnancy) are presented, grouped in 6 gestational age ranges: ≤6, 7–9, 10–12, 13–15, 16–17, and 
18–20 weeks of pregnancy. Analyses in ectopic pregnancy were restricted to samples collected until week 12 of ectopic 
gestation. C and D, Integral plasma levels of miR-324-3p and miR-27b-3p in samples from normal and ectopic pregnancies 
up to week 12 of gestation are shown. E and F, The detailed temporal course of these changes is shown. Samples from 
week 5–6 of gestation were grouped as ≤6 week, whereas those from weeks 9–12 were grouped as ≥9-week samples. Data 
are presented as medians and interquartile ranges. For presentation, data from the ≤6-week normal pregnancy group were 
used as reference values to provide relative units of expression, which were normalized against the internal control, miR-
191-5p. One asterisk indicates P<.05; 2 asterisks indicate P<.01; and 3 asterisks indicate P<.001 vs corresponding values 
in normal pregnancy (Mann-Whitney test for single comparisons in panels C and D or analysis of variance followed by 
Fisher least significant difference test). 
EP, ectopic pregnancy; NP, normal pregnancy; RU, relative units. 
Romero-Ruiz et al. Kisspeptin and miR-324-3p in ectopic pregnancy. Am J Obstet Gynecol 2019. 
  
Integral plasma levels of miR-324-3p, calculated as median and interquartile range values 
during the <12-week period, were suppressed significantly in EP vs corresponding VTOP levels, 
with a marked 80% drop in mean concentrations (Figure 4, C). This drop is in contrast with the 
observed increase in tissue levels of miR324-3p in EP, which clearly are elevated. To further 
document this discrepancy, the expression levels of the precursor, pre-miR324-3p, were assayed in 
<12-week samples from VTOP and EP. In line with the expression profile of mature microRNA, 
pre–miR324-3p levels in EP were increased significantly (Supplemental Figure S2), therefore 
confirming the divergence between tissue expression and circulating levels of this microRNA. 
Opposite to miR-324-3p, mean plasma levels of miR-27b-3p were increased moderately in EP 
during the <12-week period (Figure 4, D), which parallels the expression data of the mature 
microRNA. 
 
Timed analysis of the aforementioned changes revealed that circulating levels of miR-324-3p 
are suppressed consistently in EP all through the early gestational window (grouped at ≤6-, 7-, 8-, 
and ≥9-week samples), with statistically significant difference being detected from week 6 
onwards (Figure 4, E). In contrast, no significant changes in the plasma levels of miR-27b-3p were 
detected between control and EP, except for a transient increase in EP at gestational week 8 
(Figure 4, F). 
Circulating kisspeptin/miR-324-3p as new early biomarker of EP 
Based on the aforementioned data, biostatistics tools were used to study the usefulness of 
circulating kisspeptins and miR-324-3p as early diagnostic biomarkers of EP, measured alone or in 
combination. For validation purposes, hCG levels, as gold-standard for biochemical diagnosis of 
EP, were also measured in a representative set of VTOP and EP patients of our cohort. As shown 
in Supplemental Figure S3, total hCG concentrations were suppressed markedly in EP vs VTOP, 
when calculated as median levels over the <12-week gestational period, which is a profile that 
resembles that of kisspeptins and miR-324-3p. Time analysis at the ≤6, 7, 8, and ≥9 weeks of 
gestation revealed similar differences between control and EP, with a consistent suppression of 
hCG concentrations in EP patients, at all time-points studied. 
 
Logistic regressions were applied to evaluate the prognostic power of kisspeptin, miR-324-3p, 
total hCG, and their combinations in the prediction of EP, during the first 12 weeks of gestation. 
Logistic regression models were built with the use of the R package caret and validated with 
repeated 10-fold cross-validation. Prediction scores demonstrated the capacity of kisspeptins and 
miR-324-3p to discriminate correctly between EP and VTOP groups. Cross-validation and 
observed model performances are shown in Figure 5, A. Interestingly, the predictive power of the 
combination of kisspeptins/miR-324-3p was similar to that of hCG (Delong test; P=.6567), and 





Figure 5. Plasma kisspeptin and miR-324-3p levels as diagnostic markers of ectopic pregnancy 
A, Receiver-operating characteristic curve analyses of kisspeptins, miR-324-3p, total human chorionic gonadotropin, and 
their combinations in predicting ectopic pregnancy. Lower left panel, Performance measures of the corresponding logistic 
regression models are presented. B, A decision-tree model that was generated with the use of the miR324-3p and kisspeptin 
levels for the prediction of ectopic pregnancy is shown. 
C, control pregnancy; E, ectopic pregnancy; hCG, human chorionic gonadotropin; ROC, receiver-operating characteristic. 
Romero-Ruiz et al. Kisspeptin and miR-324-3p in ectopic pregnancy. Am J Obstet Gynecol 2019. 
Based on these findings, a decision-tree model that used miR-324-3p and kisspeptin levels was 
constructed with the use of the J48 method implemented in the R package caret and validated with 
repeated 10-fold cross-validation (AUC, 0.91±0.01; 95% confidence interval). In this model 
(Figure 5, B), the first node is based on kisspeptin levels (≤228.7 pg/mL [n=66] or ≥228.7 
pg/mL[n=43]); the second node is based on miR-324-3p levels (≤98.69 counts, n = 35, or ≥98.59 
counts, n = 31), and the third node is based on kisspeptin levels (≤85.75 pg/mL [n=18] or ≤85.75 
pg/mL [n=13]). In addition, with a similar approach, a decision-tree model that also incorporated 
total hCG levels was built (Supplemental Figure S4). In this model, the first node is based on hCG 
levels (threshold: 15,424 mIU/mL), with a second level of discrimination for values below hCG 
threshold based on kisspeptin levels (threshold: 196.91 pg/mL), and a third level based on miR-
324-3p (threshold: 43.46 counts). According to this model, for hCG levels over the threshold, 
discrimination is based on kisspeptin levels, with a nodal point at 85.75 pg/mL. 
  
Comment 
Although current strategies for detection of EP that involve transvaginal ultrasonography and 
serial determinations of β-hCG have proven reliable, false positives and negatives still occur. For 
instance, in nearly 20% of cases, EP patients display hCG profiles similar to those of intrauterine 
pregnancy; in 10% of cases, hCG levels resemble those of early miscarriage.
3
 This has prompted 
the search for novel markers of EP, which may improve the sensitivity and specificity of current 
protocols for early diagnosis. Yet, despite some promising findings,
11
 no alternative methods for 
biochemical triage of women at risk of EP at early stages of gestation are routinely in use in 
clinical practice. Likewise, the search for such novel biomarkers has not expanded substantially 
our understanding of the pathogenic mechanisms underlying ectopic placentation, which might 
help to define additional risk factors. 
 
Human placentation shares some similarities with cancer migration and metastasis.
43
 In this 
context, kisspeptins, which initially were identified as potential metastasis-suppressing factors 
abundantly expressed in the placenta, were suspected to be important players for the fine control of 
trophoblast invasion and placentation.17, 18 This placental dimension of kisspeptins was further 
attested by the proven elevation of kisspeptin levels already at early stages of human gestation.
21
 
Accordingly, a number of gestational conditions putatively that are linked to abnormal 
placentation that ranges from intrauterine growth restriction to preeclampsia have been associated 
with alterations in circulating kisspeptin levels.22, 23 Our current data unambiguously document, 
for the first time, that circulating kisspeptin levels are decreased markedly during the first trimester 
of gestation in EP, with a significant drop being already detectable at very early stages (≤6 weeks 
of gestation). This profile grossly correlated with the expression levels of KISS1 in 
embryonic/placental tissue, in keeping with a potential placental source. Importantly, very few 
studies to date have correlated the expression profiles of KISS1 and plasma kisspeptin 
concentrations during the early gestational period; disparities between tissue expression and 
circulating levels have been described at later gestational ages in some diseases, such as 
preeclampsia.
44
 In our study, the observed drop in KISS1 expression might have an impact on the 
whole process of trophoblast invasion, which is inhibited by locally produced kisspeptins,20, 45 
and might facilitate nidation at an ectopic site. Kisspeptins have been suggested also to facilitate 
initial embryo adhesion/implantation at proper endometrial sites;18, 46 high tubal expression of 
Kiss1/kisspeptin has been proposed as a mechanism to prevent ectopic implantation in rats.
47
 
Whether early deregulation of kisspeptin production might facilitate adherence at extrauterine sites 
in human pregnancy is yet to be elucidated. 
 
All studies reported to date that have demonstrated alterations in kisspeptin levels or KISS1 
expression were associative in nature and therefore did not provide mechanistic information for 
the observed changes. In contrast, our analyses also intended to identify potential mechanisms for 
deregulated KISS1/kisspeptin expression in EP. We particularly focused on the role of putative 
microRNA regulators of KISS1 that may contribute to these changes. Our rationale was double: (1) 
deregulated expression of some microRNAs has been linked to EP,27, 28, 29, 32, 33 and (2) 
microRNAs have a potential diagnostic dimension, because they are amenable for detection in 
blood samples.
30
 To our knowledge, our study is the first to address the potential direct regulation 
of KISS1 by microRNAs in a physiologic setting. Notably, despite recent evidence for epigenetic 
modulation of the KISS1 system in the brain, mainly in the context of pubertal maturation,
48
 the 
contribution of microRNA pathways in this phenomenon has not been documented to date. Based 
on a combination of bioinformatic and expression analyses, we identified 2 potential microRNA 
regulators of placental KISS1 expression, namely miR-27b-3p and miR-324-3p, because they were 
predicted to have conserved seed regions at the UTRs of the KISS1 gene and displayed detectable 
expression in embryonic/placental tissue during early gestational periods. Furthermore, opposite to 
KISS1 and kisspeptin levels, relative expression of both microRNAs was increased globally in EP 
during this period, which is compatible with the predicted repressive action of these microRNAs 
on the expression/translation of its target gene, KISS1. Admittedly, the tissue samples available did 
not permit discrimination of the specific cellular source of these microRNAs, which might operate 
intra- or even transcellularly. For similar reasons, we could not ascertain whether the elements of 
such microRNA/KISS1 system might be also expressed in the Fallopian tube, thus playing a role in 




This putative regulatory role was further interrogated in vitro, with the use of appropriate 
reporter assays. Of note, although most microRNA-target repressive interactions take place at the 
3’-UTR,
26
 microRNA-binding sites have been identified also at the promoter region of certain 
genes, which may drive suppressive or stimulatory effects on gene transcription.49, 50 This 
appeared to be the case for KISS1, for which a conserved seed region for miR-27b-3p was found in 
its promoter. However, luciferase promoter assays in HEK-293 cells failed to detect any 
significant impact of miR-27b-3p on KISS1 promoter activity, at least in our heterologous system. 
In clear contrast, over-expression of miR-324-3p in HEK-293 cells was capable of repressing 
KISS1 expression, as denoted by decreased luciferase activity that used an expression vector that 
included the 3’-UTR of KISS1. Given the heterologous nature of the assay, it remains possible that 
the net magnitude of the observed changes (roughly 30% drop) might not be indicative of the real 
extent of this repressive interaction in vivo. In addition, our present results do not exclude the 
possibility of additional contributing factors for suppressed KISS1 expression in EP. Yet, our data 
unambiguously demonstrate, for the first time, the capacity of miR-324-3p to suppress KISS1, thus 
reinforcing the plausibility that the observed increase in miR-324-3p expression in ectopic 
embryonic/placental tissue is responsible, at least partially, for reduced expression of 
KISS1/kisspeptin levels in EP (Figure 3, C). Moreover, our findings collectively suggest that 
reduced kisspeptin levels in EPs are not merely due to defective placentation, but rather the 
consequence of an orchestrated deregulation of a miR-324-3p/KISS1 pathway in ectopic 
gestational tissue. 
 
To explore the potential diagnostic value of altered expression of miR-324-3p and miR-27b-3p 
in EP, we also measured the circulating levels of both microRNAs. Surprisingly, although only a 
rather modest increase in circulating miR-27b-3p was detected in EP, which was significant only 
at week 8 of pregnancy, the circulating levels of miR-324-3p were clearly suppressed in ectopic 
gestations, with a significant reduction being already detectable at very early (<6-week) stages. 
The fact that not only the levels of this mature microRNA but also of its pre-microRNA were 
increased significantly in ectopic tissue suggests that the drop in circulating miR-324-3p 
concentrations in EP might be due to defective export of this microRNA from its 
embryonic/placental source, which may lead to tissue accumulation of miR-324-3p, which is a 
phenomenon that may further contribute, via repressive interaction with KISS1, to the reduction in 
circulating kisspeptins in EP. In any event, from a diagnostic standpoint, the concomitant marked 
suppression of kisspeptin and miR-324-3p levels offers diagnostic possibilities that were explored 
in our study. Thus, a biostatistical algorithm based on plasma levels of both factors allowed us to 
construct a decision-tree model that was successful in discriminating EP vs control pregnancy, 
with ROC AUC values that were roughly analogous to those offered by determination of hCG 
alone. Moreover, combination of total hCG with these novel factors, especially miR-324-3p, 
permitted us to further increase the discriminating power, with ROC data close to 1, although 
incorporation of these complementary markers, namely kisspeptins and miR-324-3p, should 
nullify the risk of false positives or negatives. In fact, although suppressed kisspeptin levels have 
been associated with overall risk of miscarriage,
24
 to our knowledge, no study that has linked 
changes in circulating miR-324-3p with gestational alterations has been reported to date. All these 
features reinforce the potential of this method for biochemical triage of pregnancies that are at risk 
of ectopic gestation. Additional validation in independent cohorts and confirmation of the precise 
thresholds for our regression tree models are currently in progress to further refine the diagnostic 
protocol proposed herein. 
  
In sum, our data are the first conclusively to demonstrate a suppression of KISS1/kisspeptin 
levels in EP and to support the existence of a novel miR-324-3p/KISS1 regulatory pathway, which 
is altered and may have pathophysiologic implications during early EP. Our data also are endowed 
with a promising diagnostic dimension because, pending further validation, determination of 
kisspeptins and/or miR-324-3p, alone or in combination with hCG, might allow the improvement 
of current methods for noninvasive identification of EP, with superior sensitivity and specificity. 
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Supplemental Figure S1. Bioinformatic prediction of putative microRNA regulators of human KISS1 and reporter 
constructs for in vitro analyses 
A, Bioinformatic tools were applied to identify conserved seed regions of microRNAs that may operate as regulators of 
KISS1. Three major candidates were identified: miR-324-3p and miR-137-3p (with predicted seed sequences at the 3’-UTR 
of KISS1) and miR-27b-3p (with a predicted seed region at the promoter of the gene). Details about location and sequence 
of these recognition sites are included. In addition, in the lower panels, schematics are shown of the reporter constructs that 
were used in vitro to explore the putative repressive interactions of miR-324-3p at the 3’-UTR (B, the KISS1-3’UTR-Gluc 
reporter vector) and of miR-27b-3p at the promoter (C, the KISS1-promoter-GLuc reporter vector) of KISS1. 
CMV, cytomegalovirus; Gluc, gaussia luciferase; SeAP, secreted embryonic alkaline phosphatase; SV40, simian virus 40; 
UTR, untranslated region. 





Supplemental Figure S2. Expression of pre-miR-324-3p in embryonic/placental tissue in normal and ectopic pregnancies 
Integral mean expression levels of pre-miR-324-3p in samples from normal pregnancy and ectopic pregnancy up to week 
12 of gestation are shown; ectopic pregnancy values are expressed as normalized values against normal pregnancy levels. 
The asterisk indicates P<.05 (Student t test). 
EP, ectopic pregnancy; NP, normal pregnancy. 





Supplemental Figure S3. Plasma levels of total human chorionic gonadotropin in normal and ectopic pregnancies 
A, Integral plasma levels of human chorionic gonadotropin in samples from normal and ectopic pregnancies up to week 12 
of gestation are shown; ectopic pregnancy values are expressed as normalized values against normal pregnancy levels. B, 
The detailed temporal course of these changes is shown. Samples from week 5–6 of gestation were grouped as ≤6 weeks 
samples, whereas those from week 9–12 were grouped as ≥9 week samples. Absolute levels are presented in milli-
international units per milliliters as medians and interquartile ranges. One asterisk indicates P<.05 and 3 asterisks indicate 
P<.001 vs corresponding values in normal pregnancy (A, Mann-Whitney test for single comparisons or B, analysis of 
variance followed by Fisher least significant difference test). 
EP, ectopic pregnancy; hCG, human chorionic gonadotropin; NP, normal pregnancy; UTR, untranslated region. 





Supplemental Figure S4. Decision-tree model for triage of ectopic pregnancy 
A decision-tree model that was generated with the use of a sequential combination of total human chorionic gonadotropin, 
kisspeptin, and miR324-3p kisspeptin levels for the prediction of ectopic pregnancy is depicted. For further details, see 
Methods. 
hCG, human chorionic gonadotropin. 
Romero-Ruiz et al. Kisspeptin and miR-324-3p in ectopic pregnancy. Am J Obstet Gynecol 2019. 
 
 
